CN116036054B - 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途 - Google Patents
一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途 Download PDFInfo
- Publication number
- CN116036054B CN116036054B CN202310211415.2A CN202310211415A CN116036054B CN 116036054 B CN116036054 B CN 116036054B CN 202310211415 A CN202310211415 A CN 202310211415A CN 116036054 B CN116036054 B CN 116036054B
- Authority
- CN
- China
- Prior art keywords
- lactoferrin
- patch
- solution
- chitosan
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract description 61
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract description 60
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract description 60
- 229940078795 lactoferrin Drugs 0.000 title claims abstract description 60
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract description 60
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 15
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title abstract description 13
- 229920001661 Chitosan Polymers 0.000 claims description 46
- 239000000243 solution Substances 0.000 claims description 35
- 239000004005 microsphere Substances 0.000 claims description 31
- 238000003756 stirring Methods 0.000 claims description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000839 emulsion Substances 0.000 claims description 15
- 239000012071 phase Substances 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 229960000583 acetic acid Drugs 0.000 claims description 10
- 239000012362 glacial acetic acid Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- -1 uniformly stirring Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 229920000728 polyester Polymers 0.000 claims description 7
- 238000004080 punching Methods 0.000 claims description 7
- 229920002367 Polyisobutene Polymers 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000005662 Paraffin oil Substances 0.000 claims description 5
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 101710194948 Protein phosphatase PhpP Proteins 0.000 claims description 5
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 5
- 210000001015 abdomen Anatomy 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 238000007872 degassing Methods 0.000 claims description 5
- 239000012154 double-distilled water Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 229940057995 liquid paraffin Drugs 0.000 claims description 5
- HWGNBUXHKFFFIH-UHFFFAOYSA-I pentasodium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O HWGNBUXHKFFFIH-UHFFFAOYSA-I 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 229920001296 polysiloxane Polymers 0.000 claims description 5
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000002861 polymer material Substances 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 11
- 239000002552 dosage form Substances 0.000 abstract description 6
- 230000035876 healing Effects 0.000 abstract description 4
- 229940100691 oral capsule Drugs 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000002637 fluid replacement therapy Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000050459 human LTF Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310211415.2A CN116036054B (zh) | 2023-03-07 | 2023-03-07 | 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310211415.2A CN116036054B (zh) | 2023-03-07 | 2023-03-07 | 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116036054A CN116036054A (zh) | 2023-05-02 |
CN116036054B true CN116036054B (zh) | 2024-04-26 |
Family
ID=86116589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310211415.2A Active CN116036054B (zh) | 2023-03-07 | 2023-03-07 | 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116036054B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117323418B (zh) * | 2023-10-12 | 2024-05-31 | 广州见华医学科技有限公司 | 一种含乳铁蛋白的胶囊在阻止hpv病毒感染中的用途 |
CN117462657A (zh) * | 2023-11-13 | 2024-01-30 | 广州见华医学科技有限公司 | 一种乳铁蛋白胶囊在抑菌抗炎中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998006425A1 (en) * | 1996-08-12 | 1998-02-19 | A+ Science Invest Ab | Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin |
CN204839935U (zh) * | 2015-07-27 | 2015-12-09 | 烟台海安药物研发有限公司 | 一种壳聚糖止血敷贴 |
CN106177924A (zh) * | 2016-07-15 | 2016-12-07 | 黑龙江省科学院高技术研究院 | 纳米级乳铁蛋白壳聚糖微粒的制备方法 |
GB202005097D0 (en) * | 2020-03-16 | 2020-05-20 | Mead Johnson Nutrition Co | Treatment and/or prevention of covid-19 infection |
WO2021072113A1 (en) * | 2019-10-08 | 2021-04-15 | Afyx Therapeutics A/S | Compositions for the delivery of proteins |
CN113288884A (zh) * | 2019-12-10 | 2021-08-24 | 江苏一全药业有限公司 | 含有壳聚糖的药物制剂、药物透皮贴剂及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040208916A1 (en) * | 2003-04-15 | 2004-10-21 | Nick Abbott | Patch for the transdermal administration of beneficial substances |
-
2023
- 2023-03-07 CN CN202310211415.2A patent/CN116036054B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998006425A1 (en) * | 1996-08-12 | 1998-02-19 | A+ Science Invest Ab | Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin |
CN204839935U (zh) * | 2015-07-27 | 2015-12-09 | 烟台海安药物研发有限公司 | 一种壳聚糖止血敷贴 |
CN106177924A (zh) * | 2016-07-15 | 2016-12-07 | 黑龙江省科学院高技术研究院 | 纳米级乳铁蛋白壳聚糖微粒的制备方法 |
WO2021072113A1 (en) * | 2019-10-08 | 2021-04-15 | Afyx Therapeutics A/S | Compositions for the delivery of proteins |
CN113288884A (zh) * | 2019-12-10 | 2021-08-24 | 江苏一全药业有限公司 | 含有壳聚糖的药物制剂、药物透皮贴剂及其制备方法 |
GB202005097D0 (en) * | 2020-03-16 | 2020-05-20 | Mead Johnson Nutrition Co | Treatment and/or prevention of covid-19 infection |
Non-Patent Citations (3)
Title |
---|
张雪飞等主编.《药物制剂技术》.世界图书出版广东有限公司,2020,(第2020年8月第1版),第255-256页. * |
潘道东主编.《功能性食品添加剂》.中国轻工业出版社,2006,(第2006年1月第1版),第226页. * |
载乳铁蛋白壳聚糖微球/nHA/Co复合材料的制备;徐文洲等;《口腔医学研究》;第28卷(第3期);第1.2节 * |
Also Published As
Publication number | Publication date |
---|---|
CN116036054A (zh) | 2023-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116036054B (zh) | 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途 | |
TW464511B (en) | Pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system and preparation method therefor | |
CN105997951B (zh) | 一种包含卡巴拉汀的透皮给药系统及制备方法 | |
US20100266670A1 (en) | Transdermally absorptive preparation | |
EP2651414A1 (en) | Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer | |
TW200902090A (en) | Transdermal administration device for bisoprolol | |
CN116509821A (zh) | 一种乳铁蛋白贴剂在制备用于冠状病毒引起感染性疾病治疗药物中的用途 | |
JP5837518B2 (ja) | 経皮吸収用貼付製剤 | |
TW200427471A (en) | Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor | |
CN1694699A (zh) | 含有3-甲基-1-苯基-2-吡唑啉-5-酮的透皮吸收制剂 | |
EP2887927B1 (en) | Extended release compositions of an amino-c2-c6-alkyl nitrate | |
TW201249444A (en) | Antitumor medicine comprising carbon dioxide as an active ingredient | |
JPH02250823A (ja) | マイクロカプセル剤およびその製造方法 | |
CN116327740B (zh) | 一种乳铁蛋白贴剂及其在制备用于儿童反复呼吸道感染治疗药物中的用途 | |
JP2509585B2 (ja) | 外用貼付剤 | |
CN105147642A (zh) | 一种含福莫特罗或其富马酸盐的透皮贴剂 | |
KR20240041285A (ko) | 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템 | |
CN110420335B (zh) | 一种基于多孔碳酸钙的纳米免疫制剂的制备及应用 | |
CN112107561B (zh) | 含有壳聚糖的药物制剂、药物透皮贴剂及其制备方法 | |
CN116327740A (zh) | 一种乳铁蛋白贴剂及其在制备用于儿童反复呼吸道感染治疗药物中的用途 | |
CN107951868B (zh) | 一种麝香酮贴剂及其制备方法和应用 | |
CN106692111A (zh) | 一种含有酮洛芬的皮肤外用贴剂及其制备方法 | |
CN112274496A (zh) | 一种透皮贴剂用压敏胶组合物、压敏胶材料和透皮贴剂 | |
CN109498547A (zh) | 一种平阳霉素局部注射制剂及其制备方法 | |
CN112842990B (zh) | 温控性双药制剂的制备方法以及在肿瘤术后治疗中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240401 Address after: 430000, East Floor, Building C4, Biological Innovation Park, No. 666 Gaoxin Avenue, Wuhan Donghu New Technology Development Zone, Hongshan District, Wuhan City, Hubei Province Applicant after: Hubei Chang'e Biological Co.,Ltd. Country or region after: China Address before: Unit 1305, No. 219 Zhongshan Fifth Road, Yuexiu District, Guangzhou City, Guangdong Province, 510030 Applicant before: Guangzhou Jianhua Medical Technology Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |